Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2018

Open Access 01-12-2018 | Research article

RETRACTED ARTICLE: Propofol suppresses growth, migration and invasion of A549 cells by down-regulation of miR-372

Authors: Hai Sun, Dengyu Gao

Published in: BMC Cancer | Issue 1/2018

Login to get access

Abstract

Background

Propofol, a commonly used intravenous anesthetic during cancer resection surgery, has been found to exhibit tumor inhibitory effects in vitro and in vivo. The role of propofol in lung cancer has been previously reported, whereas its action mechanism remains unclear. This study further investigated the effects of propofol on lung cancer A549 cell growth, migration and invasion, as well as the underlying mechanisms.

Methods

Cell viability, proliferation, migration, invasion and apoptosis were assessed by CCK-8 assay, BrdU assay, two chamber transwell assay and flow cytometry, respectively. The regulatory effect of propofol on microRNA-372 (miR-372) expression in A549 cells was analyzed by qRT-PCR. Cell transfection was used to change the expression of miR-372. The protein expression of key factors involving in cell proliferation, apoptosis, migration and invasion, as well as Wnt/β-catenin and mTOR pathways were analyzed by western blotting.

Results

Propofol inhibited lung cancer A549 cell viability, proliferation, migration, and invasion, but promoted cell apoptosis. Moreover, miR-372 was down-regulated in propofol-treated A549 cells. Overexpression of miR-372 abrogated the effects of propofol on proliferation, migration, invasion and apoptosis of A549 cells. Knockdown of miR-372 had opposite effects. Furthermore, propofol suppressed Wnt/β-catenin and mTOR signaling pathways by down-regulating miR-372.

Conclusion

Propofol inhibits growth, migration and invasion of lung cancer A549 cells at least in part by down-regulating miR-372 and then inactivating Wnt/β-catenin and mTOR pathways.
Literature
1.
Hung RJ, McKay JD, Gaborieau V, Boffetta P, Hashibe M, Zaridze D, Mukeria A, Szeszenia-Dabrowska N, Lissowska J, Rudnai P, et al. A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature. 2008;452(7187):633–7.CrossRefPubMed
2.
3.
Nanavaty P, Alvarez MS, Alberts WM. Lung cancer screening: advantages, controversies and applications. Cancer control : journal of the Moffitt Cancer Center. 2014;21(1):9–14.CrossRefPubMed
4.
Wakelee H, Kelly K, Edelman MJ. 50 years of progress in the systemic therapy of non-small cell lung cancer. American Society of Clinical Oncology educational book American Society of Clinical Oncology Meeting. 2014:177–89.
5.
6.
Vasileiou I, Xanthos T, Koudouna E, Perrea D, Klonaris C, Katsargyris A, Papadimitriou L. Propofol: a review of its non-anaesthetic effects. Eur J Pharmacol. 2009;605(1–3):1–8.CrossRefPubMed
7.
Hsing CH, Lin MC, Choi PC, Huang WC, Kai JI, Tsai CC, Cheng YL, Hsieh CY, Wang CY, Chang YP, et al. Anesthetic propofol reduces endotoxic inflammation by inhibiting reactive oxygen species-regulated Akt/IKKbeta/NF-kappaB signaling. PLoS One. 2011;6(3):e17598.CrossRefPubMedPubMedCentral
8.
Cui D, Wang L, Qi A, Zhou Q, Zhang X, Jiang W. Propofol prevents autophagic cell death following oxygen and glucose deprivation in PC12 cells and cerebral ischemia-reperfusion injury in rats. PLoS One. 2012;7(4):11.CrossRef
9.
Zhang L, Wang N, Zhou S, Ye W, Jing G, Zhang M. Propofol induces proliferation and invasion of gallbladder cancer cells through activation of Nrf2. Journal of experimental & clinical cancer research : CR. 2012;31:66.CrossRefPubMedCentral
10.
Du Q, Liu J, Zhang X, Zhang X, Zhu H, Wei M, Wang S. Propofol inhibits proliferation, migration, and invasion but promotes apoptosis by regulation of Sox4 in endometrial cancer cells. Brazilian journal of medical and biological research =Revista brasileira de pesquisas medicas e biologicas. 2018;51(4):e6803.CrossRefPubMedPubMedCentral
11.
Liu WZ, Liu N. Propofol inhibits lung cancer A549 cells growth and epithelial-mesenchymal transition process by up-regulation of microRNA-1284. Oncol Res. 2018.
12.
Lee HJ. Exceptional stories of microRNAs. Experimental biology and medicine (Maywood,NJ). 2013;238(4):339–43.CrossRef
13.
Pratap P, Raza ST, Abbas S, Mahdi F. MicroRNA-associated carcinogenesis in lung carcinoma. J Cancer Res Ther. 2018;14(2):249–54.CrossRefPubMed
14.
Zhu Q, Zang Q, Jiang ZM. Enhanced expression of non coding miR 92a expression is implicated in the development of lung cancer. Eur Rev Med Pharmacol Sci. 2018;22(4):1028–34.PubMed
15.
Wiggins JF, Ruffino L, Kelnar K, Omotola M, Patrawala L, Brown D, Bader AG. Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34. Cancer Res. 2010;70(14):5923–30.CrossRefPubMedPubMedCentral
16.
Wang Q, Liu S, Zhao X, Wang Y, Tian D, Jiang W. MiR-372-3p promotes cell growth and metastasis by targeting FGF9 in lung squamous cell carcinoma. Cancer Med. 2017;6(6):1323–30.CrossRefPubMedPubMedCentral
17.
Gu H, Guo X, Zou L, Zhu H, Zhang J. Upregulation of microRNA-372 associates with tumor progression and prognosis in hepatocellular carcinoma. Mol Cell Biochem. 2013;375(1–2):23–30.PubMed
18.
Yu J, Jin L, Jiang L, Gao L, Zhou J, Hu Y, Li W, Zhi Q, Zhu X. Serum miR-372 is a diagnostic and prognostic biomarker in patients with early colorectal Cancer. Anti Cancer Agents Med Chem. 2016;16(4):424–31.CrossRef
19.
Ish-Shalom S, Lichter A. Analysis of fungal gene expression by real time quantitative PCR. Methods in molecular biology (Clifton,NJ). 2010;638:103–14.CrossRef
20.
Ou W, Lv J, Zou X, Yao Y, Wu J, Yang J, Wang Z, Ma Y. Propofol inhibits hepatocellular carcinoma growth and invasion through the HMGA2-mediated Wnt/beta-catenin pathway. Experimental and therapeutic medicine. 2017;13(5):2501–6.CrossRefPubMedPubMedCentral
21.
Zhang D, Zhou XH, Zhang J, Zhou YX, Ying J, Wu GQ, Qian JH. Propofol promotes cell apoptosis via inhibiting HOTAIR mediated mTOR pathway in cervical cancer. Biochem Biophys Res Commun. 2015;468(4):561–7.CrossRefPubMed
22.
Ellett ML. Review of propofol and auxiliary medications used for sedation. Gastroenterology nursing : the official journal of the Society of Gastroenterology Nurses and Associates. 2010;33(4):284–95 quiz 296-287.CrossRefPubMed
23.
Liu XR, Cao L, Li T, Chen LL, Yu YY, Huang WJ, Liu L, Tan XQ. Propofol attenuates H2O2-induced oxidative stress and apoptosis via the mitochondria- and ER-medicated pathways in neonatal rat cardiomyocytes. Apoptosis : an international journal on programmed cell death. 2017;22(5):639–46.CrossRefPubMed
24.
Tian Y, Guo S, Guo Y, Jian L. Anesthetic Propofol attenuates apoptosis, Abeta accumulation, and inflammation induced by sevoflurane through NF-kappaB pathway in human Neuroglioma cells. Cell Mol Neurobiol. 2015;35(6):891–8.CrossRefPubMed
25.
Huang X, Teng Y, Yang H, Ma J. Propofol inhibits invasion and growth of ovarian cancer cells via regulating miR-9/NF-kappaB signal. Brazilian journal of medical and biological research =Revista brasileira de pesquisas medicas e biologicas. 2016;49(12):e5717.CrossRefPubMedPubMedCentral
26.
Ye HJ, Bai JJ, Guo PP, Wang W, Lin CS. Propofol suppresses invasion of human lung cancer A549 cells by down-regulating aquaporin-3 and matrix metalloproteinase-9. Nan fang yi ke da xue xue bao = Journal of Southern Medical University. 2016;36(9):1286–90.PubMed
27.
Wu KC, Yang ST, Hsia TC, Yang JS, Chiou SM, Lu CC, Wu RS, Chung JG. Suppression of cell invasion and migration by propofol are involved in down-regulating matrix metalloproteinase-2 and p38 MAPK signaling in A549 human lung adenocarcinoma epithelial cells. Anticancer Res. 2012;32(11):4833–42.PubMed
28.
Cui WY, Liu Y, Zhu YQ, Song T, Wang QS. Propofol induces endoplasmic reticulum (ER) stress and apoptosis in lung cancer cell H460. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 2014;35(6):5213–7.CrossRefPubMed
29.
Zhang J, Shan WF, Jin TT, Wu GQ, Xiong XX, Jin HY, Zhu SM. Propofol exerts anti-hepatocellular carcinoma by microvesicle-mediated transfer of miR-142-3p from macrophage to cancer cells. J Transl Med. 2014;12:279.CrossRefPubMedPubMedCentral
30.
Ye Z, Jingzhong L, Yangbo L, Lei C, Jiandong Y. Propofol inhibits proliferation and invasion of osteosarcoma cells by regulation of microRNA-143 expression. Oncol Res. 2013;21(4):201–7.CrossRefPubMed
31.
Cho WJ, Shin JM, Kim JS, Lee MR, Hong KS, Lee JH, Koo KH, Park JW, Kim KS. miR-372 regulates cell cycle and apoptosis of ags human gastric cancer cell line through direct regulation of LATS2. Molecules and cells. 2009;28(6):521–7.CrossRefPubMed
32.
Voorhoeve PM, le Sage C, Schrier M, Gillis AJ, Stoop H, Nagel R, Liu YP, van Duijse J, Drost J, Griekspoor A, et al. A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors. Adv Exp Med Biol. 2007;604:17–46.CrossRefPubMed
33.
Uematsu K, He B, You L, Xu Z, McCormick F, Jablons DM. Activation of the Wnt pathway in non small cell lung cancer: evidence of dishevelled overexpression. Oncogene. 2003;22(46):7218–21.CrossRefPubMed
34.
Yang L, Chen Y, Cui T, Knosel T, Zhang Q, Albring KF, Huber O, Petersen I. Desmoplakin acts as a tumor suppressor by inhibition of the Wnt/beta-catenin signaling pathway in human lung cancer. Carcinogenesis. 2012;33(10):1863–70.CrossRefPubMed
35.
Zhou AD, Diao LT, Xu H, Xiao ZD, Li JH, Zhou H, Qu LH. Beta-catenin/LEF1 transactivates the microRNA-371-373 cluster that modulates the Wnt/beta-catenin-signaling pathway. Oncogene. 2012;31(24):2968–78.CrossRefPubMed
36.
Fumarola C, Bonelli MA, Petronini PG, Alfieri RR. Targeting PI3K/AKT/mTOR pathway in non small cell lung cancer. Biochem Pharmacol. 2014;90(3):197–207.CrossRefPubMed
37.
Chen GM, Zheng AJ, Cai J, Han P. MicroRNA-145-3p inhibits non-small cell lung Cancer Cell migration and invasion by targeting PDK1 via the mTOR signaling pathway. J Cell Biochem. 2018;119(1):885–95.CrossRefPubMed
38.
Zhu J, Yao J, Huang R, Wang Y, Jia M, Huang Y. Ghrelin promotes human non-small cell lung cancer A549 cell proliferation through PI3K/Akt/mTOR/P70S6K and ERK signaling pathways. Biochem Biophys Res Commun. 2018.
Metadata
Title
RETRACTED ARTICLE: Propofol suppresses growth, migration and invasion of A549 cells by down-regulation of miR-372
Authors
Hai Sun
Dengyu Gao
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2018
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-018-5175-y

Other articles of this Issue 1/2018

BMC Cancer 1/2018 Go to the issue

Research article

Activated iNKT cells enhance the anti-tumor effect of antigen specific CD8 T cells on mesothelin-expressing salivary gland cancer

Research article

FOXA1 and AR in invasive breast cancer: new findings on their co-expression and impact on prognosis in ER-positive patients

Research article

Neutrophils to lymphocytes ratio as a useful prognosticator for stage II colorectal cancer patients

Research article

MASTL inhibition promotes mitotic catastrophe through PP2A activation to inhibit cancer growth and radioresistance in breast cancer cells

Case report

First reported case of a collision tumor composed of pancreatic adenocarcinoma and retroperitoneal liposarcoma: a case report

Research article

Structural and advanced imaging in predicting MGMT promoter methylation of primary glioblastoma: a region of interest based analysis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits